[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344765-105":59,"doc-detail-344765-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","special-issue-resistance-to-therapy-in-ovarian-cancers","Special Issue - Resistance to Therapy in Ovarian Cancers","","Editorial overview of the Special Issue focused on mechanisms and biomarkers driving resistance to therapy in epithelial ovarian cancers. Highlights the clinical heterogeneity of EOCs, limited efficacy of targeted approaches outside high-grade serous disease, and persistent chemotherapy and targeted-agent resistance. Reviews advanced-stage diagnosis, standard platinum-based treatment, major barriers from systemic toxicity and acquired resistance, and emerging strategies to overcome resistance, including combination regimens and biomarker-driven tools.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/special-issue-resistance-to-therapy-in-ovarian-cancers/344765/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/special-issue-resistance-to-therapy-in-ovarian-cancers/344765.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is therapy resistance a central challenge in epithelial ovarian cancers?","Question",{"text":112,"@type":113},"Most patients eventually develop intrinsic or acquired resistance to chemotherapy and newer targeted agents, leading to poor prognosis and limited therapeutic options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the standard treatments for advanced-stage ovarian cancer?",{"text":117,"@type":113},"Advanced-stage care typically includes cytoreductive surgery, platinum-based chemotherapy, and targeted maintenance therapies such as bevacizumab and PARP inhibitors for responders.",{"name":119,"@type":110,"acceptedAnswer":120},"Which resistance-related mechanisms are discussed in this editorial?",{"text":121,"@type":113},"Resistance mechanisms include altered drug transport, enhanced DNA repair, epithelial–mesenchymal transition, immune evasion, and changes in apoptosis and autophagy pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344765,1790189421,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Editorial  \nSpecial Issue “Resistance to Therapy in Ovarian Cancers”Eros Azzalini  and Serena Bonin *  \nReceived: 28 December 2025  \nAccepted: 22 January 2026  \nPublished: 25 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDSM—Department of Molecular Sciences, University of Trieste, 34149 Trieste, Italy; eazzalini@units.it * Correspondence: sbonin@units.it; Tel.: +39-040-3993266  \n1. Editorial  \nEpithelial ovarian cancers (EOCs) are a heterogenous group of neoplasms at the clinical, pathological, and molecular levels. Approximately 70% of EOCs are high-grade serous ovarian cancers (HGSOCs), while the less common epithelial subtypes are endometrioid, clear cell, low-grade serous, mucinous, and carcinosarcoma [1,2] . These latter subtypes are relatively rare, creating major challenges for conducting adequately powered, histotype-specific clinical trials, which contributes to the slow development of evidence-based personalized strategies [3] . Even where molecular alterations are known [4], effective targeted therapies are limited, and precision agents validated in HGSOCs show minimal or unproven benefit in non-HGSOC tumors [3] . Additionally, intrinsic and acquired resistance to chemotherapy and new targeted agents remains frequent in these subtypes, as emphasized in clinical guidelines [5] .  \nWith the exception of endometrioid ovarian and clear cell carcinomas, which often present at an earlier stage, most EOCs are diagnosed at advanced stages (III and IV) due to their non-specific symptoms, with a mean 5-year overall survival rate of approximately 47%[6–8] . The standard treatment for advanced-stage ovarian cancer consists of cytoreductive surgery, platinum-based chemotherapy, and targeted maintenance therapies such as bevacizumab and/or PARP inhibitors [1,5,9] . Currently, there are no recommended screening methods for EOCs in average-risk, asymptomatic women, and multiple large randomized controlled trials have demonstrated that annual screening with transvaginal ultrasound, CA-125 testing, or multimodal approaches does not reduce ovarian cancer mortality [1,10] .  \nPlatinum-based therapy remains the cornerstone of treatment for EOCs in both frontline and recurrent settings, and maintenance strategies with PARP inhibitors (e.g., olaparib, niraparib) are offered to patients who respond to platinum-based therapy [1,5,11] . However, the clinical utility of platinum-based therapy is limited by severe systemic toxicities—affecting the kidneys, heart, liver, and inner ear—and by the frequent emergence of resistance [12,13] . The efficacy of platinum is particularly pronounced in tumors with BRCA mutations or homologous recombination deficiency (HRD), which are more sensitive to DNA-damaging agents. Nevertheless, most patients eventually develop platinum resistance, which is associated with poor prognosis and limited therapeutic options [14] . Such resistance mechanisms include altered drug transport, enhanced DNA repair, epithelial–mesenchymal transition, immune evasion, and changes in apoptosis and autophagy pathways [12,15–17] . To overcome these hurdles, research is focused on developing less toxic cisplatin analogs and exploring combination strategies with other drugs, natural compounds, hyperthermia, or radiotherapy [12] .  \nIn this Special Issue, several mechanisms and biomarkers implicated in resistance to platinum-based therapy are presented. Among them, matrix metalloproteinase 3 (MMP3)  \nhas been associated with resistance and poor prognosis in high-grade serous ovarian cancer [18] . siRNA-mediated MMP3 knockdown was reported to reduce proliferation and invasion in cisplatin-resistant cells, showing synergistic effects when combined with cisplatin [18] . Mortalin, a chaperone involved in proliferation and migration, has also been reported to contribu","cbCaibcJUwfkEvNf","https://ap.wps.com/l/cbCaibcJUwfkEvNf","pdf",182300,"English","# Editorial\n## Clinical background of epithelial ovarian cancers\n## Standard treatment and screening limitations\n## Platinum resistance mechanisms and emerging solutions\n## Featured mechanisms and biomarkers in this Special Issue\n## PARP inhibitors and resistance after maintenance\n## Biomarker development and radiomics","[{\"question\":\"Why is therapy resistance a central challenge in epithelial ovarian cancers?\",\"answer\":\"Most patients eventually develop intrinsic or acquired resistance to chemotherapy and newer targeted agents, leading to poor prognosis and limited therapeutic options.\"},{\"question\":\"What are the standard treatments for advanced-stage ovarian cancer?\",\"answer\":\"Advanced-stage care typically includes cytoreductive surgery, platinum-based chemotherapy, and targeted maintenance therapies such as bevacizumab and PARP inhibitors for responders.\"},{\"question\":\"Which resistance-related mechanisms are discussed in this editorial?\",\"answer\":\"Resistance mechanisms include altered drug transport, enhanced DNA repair, epithelial–mesenchymal transition, immune evasion, and changes in apoptosis and autophagy pathways.\"}]","Special Issue - Resistance to Therapy in Ovarian Cancers | PDF",1790055168,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60b32c638dc84704a446c7b75016d830.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a53835de9f25c419f1e8b7894813a5f6.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ccd571ac16959c88f627f2feeca4a67.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ea10758469fd146861b2d2a0790888c.webp",980,1385]